Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use.
Abstract
Cerebral venous thrombosis (CVT) is an uncommon cause of stroke that mainly affects young adults with known risk factors of prothrombotic conditions, pregnancy, infection, malignancy, and drugs. Dutasteride is a 5α-reductase inhibitor that is used for benign prostate hypertrophy and androgenetic alopecia. To date, CVT caused by dutasteride use has not been reported. A 25-year-old male presented with headache and diplopia. He had taken 0.5 mg of dutasteride every other day for 9 months to treat alopecia. A headache developed 7 months after he started taking medication, and horizontal diplopia occurred 1 month after the onset of headache. Fundus examination showed bilateral papilledema. Brain magnetic resonance imaging showed thrombosis in the left sigmoid and transverse sinuses. Headache and diplopia improved after discontinuing dutasteride and starting anticoagulation. The results from this case report indicated dutasteride as a potential cause of CVT. Presumably, the increased estrogen level due to dutasteride use caused the formation of a thrombus.
Resumo Rápido
The results from this case report indicated dutasteride as a potential cause of CVT, Presumably, the increased estrogen level due to dutasterside use caused the formation of a thrombus.
Used In Evidence Reviews
Similar Papers
Expert opinion on pharmacotherapy · 2010
Male androgenetic alopecia.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2018
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.
Journal of the American Academy of Dermatology · 2014
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Reviews in endocrine & metabolic disorders · 2015
Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Skin therapy letter · 2012
Promising therapies for treating and/or preventing androgenic alopecia.
Journal of the American Academy of Dermatology · 2019